Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
News|Articles|July 24, 2025
- Vol. 26/No. 9
- Volume 26
- Issue 9
Cellular Therapies Begin to Make Their Mark in Solid Tumors
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.
Advertisement
Advertisement
Cellular therapies such as CAR T-cell agents and bispecific T-cell engagers (BiTEs) have had a major effect on the treatment landscape of patients with hematologic malignancies with 7 agents earning indications across subtypes of leukemia and lymphoma, as well as multiple myeloma.1 In the solid tumor realm, investigators are pushing hard to integrate this class of agents into multiple disease settings, with some notable successes already.
Related to this article
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Advertisement
Advertisement